GSE162564
Targeting p300/CBP axis in lethal prostate cancer
Treating CRPC remains challenging due to persistent AR signaling. Inhibiting transcriptional AR co-activators is an attractive therapeutic strategy. CCS1477, an inhibitor of p300/CBP, alters the transcriptome of Prostate Cancer cell models Overall design: Transcriptional Alterations in prostate cancer models after treatment with p300/CBP inhibitor, BET inhibitor, or control